TSUMURA & CO. Logo

TSUMURA & CO.

A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.

4540 | T

Overview

Corporate Details

ISIN(s):
JP3535800001
LEI:
Country:
Japan
Address:
港区赤坂二丁目17番11号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1893, Tsumura & Co. is a leading Japanese pharmaceutical company specializing in Kampo medicine, a traditional Japanese herbal therapy. The company's primary business is the manufacture and sale of prescription and over-the-counter (OTC) Kampo formulations, which are derived from natural substances. Its product portfolio also includes other medications and consumer items such as herbal bath salts. Tsumura manages an integrated value chain, from the procurement of raw medicinal herbs to the production of finished goods. The company is guided by a philosophy of achieving “Cho-WA” (harmony) between mind and body, blending tradition with scientific innovation to contribute to individual and societal well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 08:16
Interim Report
確認書
Japanese 8.9 KB
2025-11-11 08:14
Interim Report
半期報告書-第90期(2025/04/01-2026/03/31)
Japanese 267.3 KB
2025-09-10 07:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-08-05 07:44
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-07-08 07:37
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.7 KB
2025-07-01 09:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2025-06-24 06:22
Governance Information
内部統制報告書-第89期(2024/04/01-2025/03/31)
Japanese 25.7 KB
2025-06-24 06:21
Annual Report
有価証券報告書-第89期(2024/04/01-2025/03/31)
Japanese 3.5 MB
2025-06-24 06:21
Registration Form
確認書
Japanese 8.9 KB
2025-06-11 06:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.8 KB
2025-05-12 07:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.0 KB
2025-04-07 07:10
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2025-03-10 07:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-03-03 08:27
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.2 KB
2025-02-20 07:30
Share Issue/Capital Change
臨時報告書
Japanese 27.8 KB

Automate Your Workflow. Get a real-time feed of all TSUMURA & CO. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TSUMURA & CO.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TSUMURA & CO. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE
MBX Biosciences, Inc. Logo
Developing novel peptide therapies for underserved endocrine and metabolic disorders.
United States of America
MBX
Median Diagnostics Inc. Logo
Manufactures veterinary IVD kits & raw materials to diagnose infectious animal diseases.
South Korea
233250
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan
4875
Medicon Hellas S.A. Logo
Develops, makes, and sells IVD products, analytical systems & software for healthcare providers.
Greece
MEDIC
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea
054180
Medicus Pharma Ltd. Logo
A clinical-stage holding company advancing novel drugs, biologics, and devices to market.
United States of America
MDCX
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany
MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France
MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan
2370

Talk to a Data Expert

Have a question? We'll get back to you promptly.